A number of research analysts have recently weighed in on EDIT shares.
Editas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. Editas Medicine, Inc. (NASDAQ:EDIT) has returns on equity of -56.10%, which is measuring a corporation's profitability by revealing how much profit generates by EDIT with the shareholders' money. JPMorgan Chase & Co. reissued a "hold" rating on shares of Editas Medicine in a report on Sunday, February 19th.
When we look at the Analyst Recommendations of the stock, the company has 2.11 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Editas Medicine Inc. has 1 year price target of $33.5. The offering is slated to close on March 22, 2017, subject to customary closing conditions. The total market capitalization remained at $733.05 million.
The company has a 50 day moving average price of $21.84 and a 200 day moving average price of $17.26.
The 4 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 33.50, with a high estimate of 40.00 and a low estimate of 27.00.
The gross proceeds to Editas Medicine from this offering are expected to be about $90 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The company reported ($1.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.48. During the same period in the prior year, the business earned ($4.05) EPS. Equities analysts predict that Editas Medicine will post ($2.85) earnings per share for the current year.
In other Editas Medicine news, COO Alexandra Glucksmann sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $26.41, for a total value of $26,410.00. Following the transaction, the chief operating officer now owns 118,788 shares in the company, valued at $3,137,191.08. Also, CFO Andrew A.F. Hack sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $19.20, for a total transaction of $288,000.00. Following the completion of the sale, the chief financial officer now owns 15,000 shares of the company's stock, valued at $288,000. The disclosure for this sale can be found here.
In the last trading session, The Company traded 6.6 Million shares.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new position in Editas Medicine during the fourth quarter worth $284,000. PARK CIRCLE Co purchased a new position in Editas Medicine during the third quarter worth $135,000. Clough Capital Partners L P purchased a new stake in Editas Medicine during the fourth quarter worth $818,000. Finally, A.R.T. Advisors LLC purchased a new position in Editas Medicine during the fourth quarter worth $417,000.
On Dec 16 Editas Medicine Inc.
- Liverpool draw 'one of my happiest days' - Guardiola
- Analyst Consideration on: Abbott Laboratories (ABT)
- The Trump clan enjoys family vacation in Aspen
- Door for Colin Kaepernick return still open — Niners GM
- Trump to host Iraq PM at White House
- EBay Announces 'guaranteed Delivery' Service This Summer
- Harvey Norman receives 'please explain' notice from Australian stock exchange
- Downer's new Spotless shares cross, now for the raising
- Details on Watch Dogs 2 DLC, Human Conditions
- Overland Park Subdivision Ablaze After Apartment Fire Spreads